CSIMarket Company Name, Ticker, Industry, else..
 
Leonabio Inc   (LONA)
 

Leonabio Inc's Customers Performance

LONA


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
LONA's Source of Revenues

• List of LONA Customers




for the same period Leonabio Inc

• List of LONA Customers





Leonabio Inc's Comment on Sales, Marketing and Customers



The company is developing drug candidates lasofoxifene and ATH-1105 for the treatment of metastatic breast cancer and amyotrophic lateral sclerosis (ALS), respectively. Lasofoxifene is currently in a Phase 3 clinical trial targeting metastatic breast cancer with ESR1 mutations. ATH-1105 has completed Phase 1 trials and is preparing for Phase 2 studies in ALS treatment. The company focuses on oncology and neurology markets. Lasofoxifene was originally developed by Pfizer and Ligand Pharmaceuticals and approved in Europe for osteoporosis under the name Fablyn, though it was not marketed. Pfizer returned the rights to Ligand, which subsequently licensed lasofoxifene to Sermonix Pharmaceuticals. Sermonix is developing lasofoxifene for estrogen receptor-positive breast cancer with ESR1 mutation. The company plans to pursue commercialization following regulatory approvals. Customers and partners mentioned include Duke University, Ligand Pharmaceuticals, Pfizer Inc., and Sermonix Pharmaceuticals, Inc.





Leonabio Inc’s Comment on Sales, Marketing and Customers


The company is developing drug candidates lasofoxifene and ATH-1105 for the treatment of metastatic breast cancer and amyotrophic lateral sclerosis (ALS), respectively. Lasofoxifene is currently in a Phase 3 clinical trial targeting metastatic breast cancer with ESR1 mutations. ATH-1105 has completed Phase 1 trials and is preparing for Phase 2 studies in ALS treatment. The company focuses on oncology and neurology markets. Lasofoxifene was originally developed by Pfizer and Ligand Pharmaceuticals and approved in Europe for osteoporosis under the name Fablyn, though it was not marketed. Pfizer returned the rights to Ligand, which subsequently licensed lasofoxifene to Sermonix Pharmaceuticals. Sermonix is developing lasofoxifene for estrogen receptor-positive breast cancer with ESR1 mutation. The company plans to pursue commercialization following regulatory approvals. Customers and partners mentioned include Duke University, Ligand Pharmaceuticals, Pfizer Inc., and Sermonix Pharmaceuticals, Inc.







LONA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Leonabio Inc 180.08 0.00 0.00 -
SUBTOTAL 0.00 0.00 0.00 -

Sources: Leonabio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Leonabio Inc’s corporate clients.
For your research, we’ve provided 9 tables on Leonabio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.